Suha Taspolatoglu Net Worth

Suha Taspolatoglu biography

Suha Taspolatoglu M.D. serves as Independent Director of the Company. Dr. Taspolatoglu has served as a member of the board of directors of OpCo, our wholly owned subsidiary, since June 2017. Since 2013, Dr. Taspolatoglu has been working as the Chief Executive Officer of Abdi Ibrahim Ilac Sanayi ve Ticaret A.S., a pharmaceutical company. Dr. Taspolatoglu joined Abdi Ibrahim as the head of sales and marketing division in 2001 and became managing director of sales and marketing division in 2007. From 2009 to 2013, Dr. Taspolatoglu worked as the General Manager of Roche Turkey. Dr. Taspolatoglu is a graduate of Ankara University Faculty of Medicine and served from 1986 to 1989 as a physician in the Ministry of Health. Our Board believes Dr. Taspolatoglu’s background in marketing and sales in the pharmaceutical sector provides him with the qualifications and skills to serve on our Board.

How old is Suha Taspolatoglu?

Suha Taspolatoglu is 58, he's been the Independent Director of Ocugen Inc since 2019. There are 5 older and 10 younger executives at Ocugen Inc. The oldest executive at Ocugen Inc is Prabhavathi Fernandes, 71, who is the Independent Director.

What's Suha Taspolatoglu's mailing address?

Suha's mailing address filed with the SEC is C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN, PA, 19355.

Insiders trading at Ocugen Inc

Over the last 5 years, insiders at Ocugen Inc have traded over $18,069,176 worth of Ocugen Inc stock and bought 1,511,356 units worth $684,830 . The most active insiders traders include Shankar Musunuri, Junge Zhang oraz Uday Kompella. On average, Ocugen Inc executives and independent directors trade stock every 21 days with the average trade being worth of $96,347. The most recent stock trade was executed by Junge Zhang on 14 June 2023, trading 200,278 units of OCGN stock currently worth $100,139.

What does Ocugen Inc do?

ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.

Ocugen Inc executives and stock owners

Ocugen Inc executives and other stock owners filed with the SEC include:

• Dr. Shankar Musunuri M.B.A., MBA, Ph.D.,
  Co-Founder, Chairman & CEO
• Shankar Musunuri,
  Chairman of the Board, Chief Executive Officer
• Sanjay S. Subramanian M.B.A.,
  Chief Accounting Officer, CFO, Treasurer, Head of Corp. Devel. & Corp. Sec.
• Rasappa Arumugham,
  Chief Scientific Officer
• Dr. Uday B. Kompella Ph.D.,
  Co-founder & Independent Director
• Junge Zhang,
  Independent Director
• Suha Taspolatoglu,
  Independent Director
• Manish Potti,
  Independent Director
• Ramesh Kumar,
  Independent Director
• Uday Kompella,
  Independent Director
• Prabhavathi Fernandes,
  Independent Director
• Kirsten Castillo,
  Independent Director
• Kelly Beck,
  Vice President, Investor Relations and Administration and Corporate Secretary
• Vijay Tammara,
  Senior Vice President - Regulatory and Quality
• Sanjay Subramanian,
  Chief Financial Officer, Chief Accounting Officer, Treasurer
• Michael Shine,
  Sr. VP of Commercial
• J. P. Gabriel,
  Sr. VP of Manufacturing & Supply Chain
• Dr. Bruce D. Forrest B.S., M.B.A., M.D.,
  Acting Chief Medical Officer & Vaccine Scientific Advisory Board Member
• Dr. Arun Upadhyay Ph.D.,
  Head of Research, Devel. & Discovery
• Dr. Vijay Tammara,
  Sr. VP of Regulatory & Quality
• Zara Gaudioso,
  Head of HR
• Ken Inchausti,
  Head of Investor Relations & Communications
• Jessica Crespo,
  CAO/SVP, Finance
• Daniel Jorgensen,
  Chief Medical Officer
• Frank Leo,
  Director
• Marna C Whittington,
  Director
• Huma Qamar,
  Chief Medical Officer
• Arun Upadhyay,
  See Remarks